- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04736199
Darolutamid jako doplněk k ADT versus ADT u metastatického karcinomu prostaty citlivého na hormony (ARANOTE)
Randomizovaná, dvojitě zaslepená, placebem kontrolovaná studie fáze 3 darolutamidu jako doplněk k terapii nedostatku androgenu (ADT) versus placebo plus ADT u mužů s metastatickým hormonálně senzitivním karcinomem prostaty (mHSPC)
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
New South Wales
-
Kingswood, New South Wales, Austrálie, 2747
- Nepean Hospital
-
St Leonards, New South Wales, Austrálie, 2065
- Northern Cancer Institute
-
Sydney, New South Wales, Austrálie, 2109
- Macquarie University Hospital - Oncology Department
-
-
South Australia
-
Adelaide, South Australia, Austrálie, 5000
- Cancer Research South Australia
-
-
Victoria
-
Frankston, Victoria, Austrálie, 3199
- Peninsula Oncology Centre
-
Heidelberg, Victoria, Austrálie, 3084
- Austin Health
-
-
-
-
-
Rio de Janeiro, Brazílie, 22793-080
- Instituto COI de Educação e Pesquisa
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazílie, 41950-640
- Assistência Multidisciplinar em Oncologia (AMO)
-
-
Goiás
-
Goiânia, Goiás, Brazílie, 74605-070
- Hosp. Araujo Jorge da Associação de Combate ao Câncer
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazílie, 30130-100
- Hospital da Universidade Federal de Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazílie, 30150-270
- Cetus Oncologia Hospital Dia
-
-
Paraná
-
Curitiba, Paraná, Brazílie, 81520-060
- Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brazílie, 59040-000
- Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica
-
-
Rio Grande do Sul
-
Pelotas, Rio Grande do Sul, Brazílie, 96020-080
- Unidade de Pesquisas Clinicas em Oncologia
-
Porto Alegre, Rio Grande do Sul, Brazílie, 90850-170
- Hospital Mae de Deus
-
Porto Alegre, Rio Grande do Sul, Brazílie, 91350-280
- FZ Pesquisa e Servicos em Cardiologia | Porto Alegre, Brazil
-
Porto Alegre, Rio Grande do Sul, Brazílie, 90020-090
- Santa Casa de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia
-
-
São Paulo
-
Barretos/SP, São Paulo, Brazílie, 14784-400
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
São José do Rio Preto, São Paulo, Brazílie, 15090-000
- Hospital de Base | Funfarme - Centro Integrado de Pesquisa - Cardiologia
-
São Paulo, São Paulo, Brazílie, 03102-002
- IBCC - Instituto Brasileiro de Controle do Cancer
-
São Paulo, São Paulo, Brazílie, 01243-020
- Urobrasil
-
São Paulo, São Paulo, Brazílie, 04039-004
- Inst. de Assistência Médica ao Sérvidor Público Estadual
-
-
-
-
-
Santiago, Chile, 7510032
- Oncovida
-
Santiago, Chile
- UROMED
-
Santiago, Chile, TBC
- Hospital Clínico de la Pontificia Univ. Católica de Chile
-
Santiago, Chile, 7500921
- Fundación Arturo López Perez
-
-
Araucania
-
Temuco, Araucania, Chile, 4781156
- Centro de Investigación Clínica del Sur
-
-
Santiago Metropolitan
-
Providencia, Santiago Metropolitan, Chile, 7500653
- Centro de Estudios Clínicos SAGA SpA
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- OncoCentro
-
-
-
-
-
Chandigarh, Indie, 160012
- Post Graduate Institute of Medical Education and Research
-
Kolkata, Indie, 700156
- Tata Medical Center
-
Nashik, Indie, 422009
- Apex Wellness Hospital
-
New Delhi, Indie, 110 085
- Rajiv Gandhi Cancer Institute & Research Centre
-
-
Andhra Pradesh
-
Visakhapatnam, Andhra Pradesh, Indie, 530017
- Mahatma Gandhi Cancer Hospital & Research Institute
-
-
Gujarat
-
Ahmedabad, Gujarat, Indie, 380016
- The Gujarat Cancer & Research Institute
-
Ahmedabad, Gujarat, Indie, 380060
- HCG Cancer Centre - Ahmedabad
-
Vadodara, Gujarat, Indie, 390007
- Cancer Care Clinic - Vadodara
-
-
Karnataka
-
Belagavi, Karnataka, Indie, 590010
- K.L.E.S. Dr. Prabhakar Kore Hospital & Medical Research Centre
-
Bengaluru, Karnataka, Indie, 560027
- Healthcare Global Enterprises Ltd
-
-
Kerala
-
Kochi, Kerala, Indie, 682 041
- Amrita Institute of Medical Sciences
-
Thiruvananthapuram, Kerala, Indie, 695011
- Regional Cancer Centre - Thiruvananthapuram
-
-
Maharashtra
-
Chhatrapati Sambhajinagar, Maharashtra, Indie, 431001
- Marathwada Regional Cancer Centre and Research Institute
-
Mumbai, Maharashtra, Indie, 400026
- Jaslok Hospital and Research Centre
-
Nashik, Maharashtra, Indie, 422004
- Curie Manavata Cancer Centre
-
Pune, Maharashtra, Indie, 411001
- Jehangir Hospital
-
-
Odisha
-
Bhubaneswar, Odisha, Indie, 751019
- All India Institute of Medical Sciences
-
Bhubaneswar, Odisha, Indie, 751007
- Sparsh Hospital & Critical Care
-
-
Puducherry
-
Gorimedu, Puducherry, Indie, 605006
- Jawaharlal Institute Of Postgraduate Medical Education and R
-
-
Punjab
-
Ludhiana, Punjab, Indie, 141008
- Christian Medical Center & Hospital
-
-
Rajasthan
-
Jaipur, Rajasthan, Indie, 302017
- Sawami Man Singh (SMS) Medical College & Attached Hospitals
-
-
Tamil Nadu
-
Madurai, Tamil Nadu, Indie, 625020
- Apollo Speciality Hospitals
-
Madurai, Tamil Nadu, Indie, 625107
- Meenakshi Mission Hospital & Research Centre
-
-
-
-
-
Cape Town, Jižní Afrika, 7570
- Cape Town Oncology Trials
-
-
Eastern Cape
-
Port Elizabeth, Eastern Cape, Jižní Afrika, 6045
- Cancercare Langenhoven
-
-
Gauteng
-
Johannesburg, Gauteng, Jižní Afrika, 1475
- East Rand Medical Research Unit
-
Pretoria, Gauteng, Jižní Afrika, 2
- University of Pretoria, Clinical Research Unit
-
-
-
-
Ontario
-
Burlington, Ontario, Kanada, L7N 3V2
- G. Kenneth Jansz Medicine Professional Corporation
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X 0A9
- Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM)
-
-
-
-
-
Kaunas, Litva, LT-50009
- The Hospital of Lithuanian University of Health SciencesLUHS
-
Klaipėda, Litva, LT-92288
- PI Klaipedos University Hospital
-
Vilnius, Litva, LT-08660
- National Cancer Institute
-
Vilnius, Litva, LT-08661
- Vilnius University Hospital Santaros Klinikos
-
-
-
-
-
Daugavpils, Lotyšsko, LV-5417
- Daugavpils Regional Hospital
-
Riga, Lotyšsko, 1038
- RAKUS Hospital Gailezers
-
Riga, Lotyšsko, LV-1001
- URO Ltd.
-
Riga, Lotyšsko, LV-1002
- P. Stradins Clinical University Hospital
-
Valmiera, Lotyšsko, LV-4201
- Vidzemes Hospital
-
-
-
-
Bay of Plenty
-
Tauranga, Bay of Plenty, Nový Zéland, 3112
- Tauranga Urology Research Limited
-
-
Canterbury
-
Christchurch, Canterbury, Nový Zéland, 8013
- Canterbury Urology Research Trust
-
-
Waikato Region
-
Hamilton, Waikato Region, Nový Zéland, 3240
- Waikato Hospital
-
-
-
-
-
Lima, Peru, LIMA 11
- Hospital Militar Luis Arias Schreiber
-
Lima, Peru, LIMA 27
- Clínica El Golf
-
-
Lima region
-
San Isidro, Lima region, Peru, 15036
- Aliada
-
Santiago de Surco, Lima region, Peru, 15033
- Hospital Guillermo Almenara Irigoyen
-
-
-
-
-
Arkhangelsk, Rusko, 163045
- Arkhangelsk Clinical Oncology Dispensary
-
Chelyabinsk, Rusko, 454087
- Chelyabinsk Regional Oncology Dispensary
-
Chelyabinsk, Rusko, 454048
- Ltd "EVIMED"
-
Ivanovo, Rusko, 153040
- Ivanovo Regional Oncology Dispensary
-
Kazan', Rusko, 420029
- Republican Clinical Oncology Dispensary Kazan
-
Moscow, Rusko, 117997
- Research Centre of X-ray and Radiology
-
Nizhny Novgorod, Rusko, 603109
- Volga District Med Center FMBA
-
Novosibirsk, Rusko, 630099
- LLC Reafan
-
Novosibirsk, Rusko, 630099
- Medical Center "Avicenna"
-
Omsk, Rusko, 644013
- Clinical Oncological Dispensary of Omsk Region
-
Saint Petersburg, Rusko, 196006
- AV Medical Group
-
Saint Petersburg, Rusko, 197758
- Russian Scientific Radiology and Surgery Technologies Center
-
Saint Petersburg, Rusko, 197758
- Scientific Research Instutute of Oncology n.a. N.N. Petrov
-
Tyumen, Rusko, 625041
- Multi-Field Clinical Medical Center "Medical City"
-
Ufa, Rusko, 450054
- Republican Clinical Oncology Dispensary
-
Vologda, Rusko, 160022
- Vologda Regional Hospital
-
Yekaterinburg, Rusko, 620102
- Sverdlovsk Regional Clinical Hospital #1
-
-
-
-
-
Changhua, Tchaj-wan, 50006
- Changhua Christian Hospital
-
Taichung, Tchaj-wan, 40705
- Taichung Veterans General Hospital
-
Tainan, Tchaj-wan, 704
- National Cheng Kung University Hospital
-
Taipei, Tchaj-wan, 11217
- Taipei Veterans General Hospital
-
-
Kaohsiung
-
Kaohsiung City, Kaohsiung, Tchaj-wan, 807377
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
-
-
-
-
Cherkasy, Ukrajina, 18009
- CNE "Clinical Center of Oncology, Hematology, Transplantology and Palliative Care of the Cherkasy Regional Council"
-
Dnipro, Ukrajina, 49102
- City Dnipropetrovsk Multi- field Clinical Hosp. 4 DSMA
-
Kyiv, Ukrajina, 4107
- Kyiv Regional Oncological Dispensary
-
Kyiv, Ukrajina, 02660
- Kyiv City Hospital #3 - Department of Urology
-
-
-
-
-
Beijing, Čína, 100142
- Beijing Cancer Hospital
-
Beijing, Čína, 100083
- Peking University Third Hospital
-
Beijing, Čína, 100000
- Cancer Hospital, Chinese Academy of Medical Sciences
-
-
Anhui
-
Hefei City, Anhui Province, Anhui, Čína, 230031
- Anhui Provincial Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Čína, 100730
- Beijing Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, Čína, 510000
- Sun Yat-sen University Cancer Center
-
Guangzhou, Guangdong, Čína, 510180
- Guangzhou First People Hospital
-
Shenzhen, Guangdong, Čína, 518172
- Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
-
-
Hubei
-
Wuhan, Hubei, Čína, 430030
- Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
-
Wuhan, Hubei, Čína, 430079
- Hubei Cancer Hospital
-
Wuhan, Hubei, Čína, 430071
- Zhongnan hospital ,Wuhan University
-
-
Hunan
-
Changsha, Hunan, Čína, 410013
- Hunan Cancer Hospital - Oncology Department
-
-
Jiangsu
-
Nanjing, Jiangsu, Čína, 210008
- NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
-
Nantong, Jiangsu, Čína, 226361
- Nantong tumor hospital
-
Suzhou, Jiangsu, Čína, 215004
- The 2nd Affiliated Hospital of Soochow University
-
-
Jilin
-
Changchun, Jilin, Čína, 130021
- 1st Hospital of Jilin University
-
-
Liaoning
-
Shengyang, Liaoning, Čína, 110042
- Liaoning Cancer Hospital and Institute
-
-
Shandong
-
Yantai, Shandong, Čína, 264000
- Yantai Yuhuangding Hospital
-
-
Shanxi
-
Xi’an, Shanxi, Čína, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, Čína, 610072
- SichuanAcademyofMedicalSciences&SichuanProvincialPeople'sHos
-
Chengdu, Sichuan, Čína, MISSING
- Sichuan University West China Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, Čína, 310000
- The 1st Affiliated Hospital of Zhejiang University
-
Hangzhou, Zhejiang, Čína, 310014
- ZheJiang Provincial People's Hospital
-
Ningbo, Zhejiang, Čína, 315010
- Ningbo First Hospital
-
Wenzhou, Zhejiang, Čína, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Barcelona, Španělsko, 08025
- Fundacio Puigvert | Urologia
-
Barcelona, Španělsko, 08208
- Parc Tauli Hospital Universitari | Oncologia
-
Cáceres, Španělsko, 10003
- Hospital San Pedro De Alcantara | Oncologia
-
Málaga, Španělsko, 20910
- Hospital Universitario Virgen De La Victoria | Urologia
-
Seville, Španělsko, 41013
- Hospital Universitario Virgen Del Rocio S.L. | Urologia
-
-
Madrid
-
Alcorcón, Madrid, Španělsko, 28922
- Hospital Universitario Fundacion Alcorcon | Urologia
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of prostate
- Metastatic disease
- Started ADT (LHRH agonist/antagonist or orchiectomy) with or without first generation anti-androgen, but not earlier than 12 weeks before randomization
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
- Adequate bone marrow, liver and renal function
Exclusion Criteria:
- Prior treatment with: LHRH agonist/antagonists except neoadjuvant and /or adjuvant therapy; Second-generation androgen receptor (AR) inhibitors such as enzalutamide, darolutamide, apalutamide or other investigational AR inhibitors; Cytochrome P17 enzyme inhibitor such as abiraterone acetate or oral ketoconazole as anti-cancer treatment for prostate cancer; Chemotherapy including docetaxel or immunotherapy for prostate cancer; Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days prior to randomization; Radiopharmaceuticals; Any other anti-cancer treatment for prostate cancer, excluding local therapies and ADT.
- Treatment with radiotherapy within 2 weeks before randomization
- Contraindication to iodinated CT and gadolinium chelate MRI intravenous contrast agent(s)
- Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure (New York Heart Association Class III or IV)
- Uncontrolled hypertension as indicated by a resting systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite medical management
- A gastrointestinal (GI) disorder or procedure which is expected to interfere significantly with absorption of study drug
- Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization
- Inability to swallow oral medications
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Darolutamide+ADT
Participants will receive darolutamide 600 mg (2 tablets of 300 mg) twice daily with food and ADT of investigator's choice as standard therapy |
Coated tablet, oral administration Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy |
|
Komparátor placeba: Placebo+ADT
Participants will receive placebo twice daily with food and ADT of investigator's choice as standard therapy |
Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy Coated tablet matching Darolutamide in appearance, oral administration |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Radiological Progression-free Survival (rPFS) Assessed by Central Review
Časové okno: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
rPFS used conventional imaging method (99mTc-phosphonate bone scan, CT/MRI scan). rPFS was defined as the time from the date of randomization to the date of progressive disease in malignant soft tissue lesions, progressive disease in malignant bone lesions, or death due to any cause, whichever occurs first. Malignant soft tissue lesions were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and malignant bone lesions were assessed by Prostate Cancer Clinical Trials Working Group (PCWG3) criteria. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall Survival (OS)
Časové okno: From randomization to the final analysis date, approximately 47 months
|
Time from the date of randomization to the date of death from any cause. |
From randomization to the final analysis date, approximately 47 months
|
|
Time to Castration-Resistant Prostate Cancer (CRPC)
Časové okno: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to the date of first castration resistant event (radiological progression, Prostate-specific antigen (PSA) progression or symptomatic skeletal events, whichever occurs first). |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to Initiation of Subsequent Anti-cancer Therapy
Časové okno: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to initiation of first subsequent anti-cancer therapy for prostate cancer. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to PSA Progression
Časové okno: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Time from the date of randomization to the date of first prostate-specific antigen (PSA) progression. PSA progression with serum testosterone being at castrate level <0.50 ng/mL, is defined as a ≥25% increase above the nadir (lowest at or after baseline) value and an increase in absolute value of ≥2 ng/mL above nadir, and is at least 12 weeks from randomization date, which is confirmed by a second value 3 or more weeks later. All PSA values between the initial assessment meeting the PSA progression criteria and confirmation assessment must be ≥2 ng/mL and ≥25% increase above nadir, serum testosterone at castrate levels <0.50 ng/mL is requested at initial assessment. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
PSA Undetectable Rates (<0.2 ng/mL)
Časové okno: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Percentage of subjects with detectable PSA values of ≥0.2 ng/mL at baseline which became undetectable with any PSA values <0.2 ng/mL during the period between randomization and 30 days after last dose of study drug or start of new anti-cancer therapy whichever occurred earliest, based on the subjects had detectable PSA value at baseline. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Time to Pain Progression
Časové okno: From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
Pain progression was assessed by Question 3 (Q3) of the BPI-SF questionnaire related to the worst pain in the last 24 hours (worst pain subscale [WPS]) taken as an average for post baseline score, or initiation of short or long-acting opioids for malignant disease for ≥7 consecutive days after randomization. Pain progression was defined as: (1) for asymptomatic subjects with WPS=0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization; (2) for symptomatic subjects with WPS >0 at baseline, an increase of 2 or more points in the WPS score from nadir observed at 2 consecutive evaluations ≥4 weeks apart and a WPS ≥5, or initiation of short- or long-acting opioid use for malignant disease for ≥7 consecutive days after randomization. |
From randomization to the date when 222 rPFS events were observed, approximately 36 months
|
|
Number of Participants With Adverse Events as a Measure of Safety
Časové okno: From start of study drug administration until 30 days after the last administration
|
An AE is any untoward medical occurrence in a patient or clinical study participant, after providing written IC for participation in the study, may or may not be temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AE (TEAE) is defined as any event arising or worsening after the first dose of study drug until 30 days after the last dose of study drug. |
From start of study drug administration until 30 days after the last administration
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Publikace a užitečné odkazy
Obecné publikace
- Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP; ARANOTE Study Investigators. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024 Dec 20;42(36):4271-4281. doi: 10.1200/JCO-24-01798. Epub 2024 Sep 16.
- Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M, Verholen F, Srinivasan S, Haresh KP. Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial. Eur Urol. 2026 Aug 12:S0302-2838(26)02313-4. doi: 10.1016/j.eururo.2026.07.026. Online ahead of print.
- Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2026 May;27(5):614-624. doi: 10.1016/S1470-2045(26)00014-8. Epub 2026 Apr 9.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění genitálií
- Genitální novotvary, muži
- Urogenitální novotvary
- Novotvary podle místa
- Novotvary
- Onemocnění pohlavních orgánů, muž
- Onemocnění prostaty
- Mužská urogenitální onemocnění
- Novotvary prostaty
- Fyziologické účinky léků
- Hormony, hormonální náhražky a antagonisté hormonů
- Antagonisté hormonů
- Farmakologické akce
- Chemické účinky a použití
- Antagonisté androgenů
- darolutamid
Další identifikační čísla studie
- 21140
- 2020-003093-48 (Číslo EudraCT)
- 2022-502244-12-00 (Jiný identifikátor: CTIS (EU))
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .